Ex vivo Cutaneous Bioavailability of Topical Mometasone Furoate in an O/W Preparation | Zendy

Johannes Wohlrab | Zendy; Reinhard H.H. Neubert | Zendy; Elfi Sommer | Zendy; Julia Michael | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ex vivo Cutaneous Bioavailability of Topical Mometasone Furoate in an O/W Preparation

Author(s) -

Johannes Wohlrab,

Reinhard H.H. Neubert,

Elfi Sommer,

Julia Michael

Publication year - 2016

Publication title -

skin pharmacology and physiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.703

H-Index - 74

eISSN - 1660-5535

pISSN - 1660-5527

DOI - 10.1159/000452743

Subject(s) - mometasone furoate , bioavailability , pharmacokinetics , pharmacology , dermatology , chemistry , in vivo , ex vivo , medicine , corticosteroid , in vitro , surgery , biology , biochemistry , microbiology and biotechnology

Mometasone furoate (MMF) is a modern glucocorticoid of the 4th generation, which has been proven not only for inhalation but also for cutaneous treatment. Due to its lipophilic character, it is mainly used in ointments and creams with an outer lipophilic phase (W/O type). However, this study investigated the cutaneous cytotoxicology of MMF and tried to characterize its pharmacokinetic effects on the skin using an O/W preparation. An HPLC method has been developed and validated for the detection of MMF in cutaneous tissue, and concentration-time curves of MMF were created after cutaneous application on unaffected as well as lesional skin. Cytotoxicological characterization was carried out using scratch assays on keratinocytes and cutaneous fibroblasts. Results showed that the condition of the skin had no significant impact on the cutaneous bioavailability of MMF, but the intrinsic effect of the O/W vehicle could be utilized in periods of acute inflammation. Cytotoxicological data gave no new indications regarding the safety of MMF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research